10.66USD+2.30%Mkt Cap: 657.05M USDP/E: —Last update: 2026-06-01
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The compa…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap657.05M USD
Enterprise Value434.46M USD
Revenue (TTM)—
Gross Profit-58.13M USD
Net Income (TTM)-69.79M USD
Revenue/Share—
Last Price10.66 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees54
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.41
PEG—
EV/EBITDA-5.59
EV/Revenue—
P/S—
P/B3.00
EPS (TTM)-1.20
EPS (Forward)-1.64
52W Range
3.33053% of range17.25
52W High17.25 USD
52W Low3.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.84%
ROA-30.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)193.00K USD
FCF Margin—
FCF Yield-4.80%
Net Debt-220.09M USD
Net Debt/EBITDA2.83
Balance Sheet
Debt/Equity0.01
Current Ratio22.28
Quick Ratio22.05
Book Value/Sh3.492 USD
Cash/Share3.568 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)21.00 USD
Target Range20.00 USD – 22.00 USD
# Analysts6
Ownership
Shares Out.62.46M
Float35.36M
Insiders31.93%
Institutions61.33%
Short Interest
Short Ratio4.9d
Short % Float6.16%
Short % Out.4.65%
Shares Short2.90M
Short (prev mo.)2.24M
Technical
SMA 5012.37 (-13.8%)
SMA 2009.184 (+16.1%)
Beta1.74
S&P 52W Chg27.94%
Avg Vol (30d)1.02M
Avg Vol (10d)1.79M
Technical Indicators
RSI (14)36.3
MACD-0.6173
MACD Signal-0.2428
MACD Hist.-0.3746
BB Upper16.71 USD
BB Middle12.83 USD
BB Lower8.944 USD
BB Width60.56%
ATR (14)1.135 USD
Vol Ratio (20d)0.88x